Hypereosinophilic Syndrome Has First FDA Approved Therapy in 14 Years
source: pixabay.com

Hypereosinophilic Syndrome Has First FDA Approved Therapy in 14 Years

This week, the US FDA announced that they approved the drug Nucala (mepolizumab) to treat patients with hypereosinophilic syndrome, a rare chronic blood disease which causes organ damage. Nucala is…

Continue Reading Hypereosinophilic Syndrome Has First FDA Approved Therapy in 14 Years

Editor’s Choice: Can Machine Learning Help Rare Patients Get Diagnosed and Treated Faster?

Happy Friday! October is Dysautonomia Awareness Month. Dysautonomia is a collection of conditions that affect the autonomic nervous system. This can lead to a loss of control of the body's…

Continue Reading Editor’s Choice: Can Machine Learning Help Rare Patients Get Diagnosed and Treated Faster?
Nucala Granted Priority Review as Possible Biologic Treatment For HES
source: pixabay.com

Nucala Granted Priority Review as Possible Biologic Treatment For HES

As reported in GSK, the FDA has just granted priority review to Nucala (mepolizumab), a targeted biological treatment to help patients with hypereosinophilic syndrome (HES). If the medication is accepted,…

Continue Reading Nucala Granted Priority Review as Possible Biologic Treatment For HES
Nucala Granted Priority Review For Treatment of Hypereosinophilic Syndrome
PhotoLizM / Pixabay

Nucala Granted Priority Review For Treatment of Hypereosinophilic Syndrome

  According to a drug filing and press release from Pharmaceutical Business Review, the FDA granted a priority review to GlaxoSmithKline for their humanized monoclonal antibody therapy, Nucala (mepolizumab). Currently,…

Continue Reading Nucala Granted Priority Review For Treatment of Hypereosinophilic Syndrome
Eosinophilic Asthma Treatment Nucala has FDA Approval Expanded to Children Aged 6 to 11
Source: Pixabay

Eosinophilic Asthma Treatment Nucala has FDA Approval Expanded to Children Aged 6 to 11

According to a press release from global pharmaceuticals titan GlaxoSmithKline, the US Food and Drug Administration (FDA) recently expanded approval of the Company's eosinophilic asthma treatment Nucala (generic name mepolizumab)…

Continue Reading Eosinophilic Asthma Treatment Nucala has FDA Approval Expanded to Children Aged 6 to 11

Orphan Drug Designation Given to New Potential Oral Therapy for Hypereosinophilic Syndrome

Hypereosinophilic Syndrome Hypereosinophilic syndrome (HES) is a rare disease which causes high levels of white blood cells in the body. These cells are called eosinophils, and they're essential for proper…

Continue Reading Orphan Drug Designation Given to New Potential Oral Therapy for Hypereosinophilic Syndrome

Orphan Drug Designation Granted to Potential New Hypereosinophilic Syndrome Treatment

Hypereosinophilic syndrome Hypereosinophilic syndrome (HES) refers to a group of rare conditions characterized by high levels of eosinophils which result in organ damage. These eosinophils often affect the lungs, heart, skin,…

Continue Reading Orphan Drug Designation Granted to Potential New Hypereosinophilic Syndrome Treatment
Know All About It! Register for Hypereosinophilic Syndrome Conference in March 2018
fill / Pixabay

Know All About It! Register for Hypereosinophilic Syndrome Conference in March 2018

No one knows how difficult living with hypereosinophilic syndrome (HES) is unless you walk in the shoes of those who have it, treat it, or have a loved one who…

Continue Reading Know All About It! Register for Hypereosinophilic Syndrome Conference in March 2018
A Hypereosinophilic Syndrome Inspiration: Read This Woman’s Story
https://pixabay.com/en/workout-girl-weights-fitness-1420741/

A Hypereosinophilic Syndrome Inspiration: Read This Woman’s Story

Not only does Pamela Looney have hypereosinophilic syndrome (HES), she also has asthma and has suffered from a tumor. At only 15, the sudden development of this tumor severely affected…

Continue Reading A Hypereosinophilic Syndrome Inspiration: Read This Woman’s Story
Close Menu